Kornimate/medical-research-clean huggingface dataset:
a comparison of zidovudine (azt) used alone or in combination with didanosine (ddi) or dideoxycytidine (ddc) in hiv-infected patients

Conditions: HIV Infections

Summary: primary: to compare the efficacy of zidovudine ( azt ) given alone versus azt plus didanosine ( ddi ) versus azt plus zalcitabine ( dideoxycytidine; ddc ) in delaying the occurrence of aids-related conditions in hiv-infected patients. secondary: to compare the frequency and severity of adverse experiences in the three regimens. to compare the mortality rates in the three regimens. to compare the effects of antiretroviral regimens on cd4+ cell levels. studies have indicated that maintenance therapy with azt over extended periods may be limited by dose-dependent toxicity, primarily myelosuppression, and by the emergence of drug-resistant hiv strains. it is anticipated that the combination of azt with either ddi or ddc may promote higher antiviral efficacy, with acceptable toxicity and less likelihood of development of drug-resistant strains, than azt alone.

studies have indicated that maintenance therapy with azt over extended periods may be limited by dose-dependent toxicity, primarily myelosuppression, and by the emergence of drug-resistant hiv strains. it is anticipated that the combination of azt with either ddi or ddc may promote higher antiviral efficacy, with acceptable toxicity and less likelihood of development of drug-resistant strains, than azt alone. approximately 1200 patients are randomized in a 2:1:1:2 ratio to one of the following four treatment arms: azt plus ddi, azt plus ddi placebo, azt plus ddc placebo, and azt plus ddc. average follow-up is 2 years.

Eligibility criteria:
inclusion criteria required: * documented hiv infection or working diagnosis of hiv or evidence of idiopathic suppression with an aids-defining opportunistic infection or malignancy (except kaposi's sarcoma). * cd4+ cell count = or \< 200/mm3 or = or \< 15 percent of total lymphocyte count within previous 90 days or history of aids-defining opportunistic infection. * current pcp prophylaxis. exclusion criteria co-existing condition: patients with the following symptoms and conditions are excluded: * symptoms of pancreatitis or peripheral neuropathy of grade 2 or worse. * requirement for acute therapy for any active aids-defining opportunistic infection or systemic chemotherapy for malignancy. * stage 2 or worse (moderate) aids dementia complex. * other disorders or conditions for which the study drugs are contraindicated or that may prevent adequate compliance with study therapy. concurrent medication: excluded: * acute therapy for active aids-defining opportunistic infection. * systemic chemotherapy for malignancy. * antiretroviral therapy other than that provided by this study. patients with the following prior conditions are excluded: * history of pancreatitis or peripheral neuropathy of grade 2 or worse. * history of intolerance to the study drugs at entry doses and/or frequencies. * history of phenylketonuria.

Keywords: zalcitabine didanosine drug therapy, combination acquired immunodeficiency syndrome aids-related complex zidovudine
longitudinal assessment of bone growth in children with cerebral palsy

Conditions: Cerebral Palsy; Bone Density

Summary: in 2003, observational growth and bone density data was obtained on children with cerebral palsy (cp) living at hattie larlham as part of a study comparing growth with an existing database of children with cp who live at home. the original residents included in that study are now of adult age. due to the lack of longitudinal bone density measurements in facility-based adults with severe cp, the investigators' objective is to obtain 6-year follow-up data from the residents enrolled in the original study.


Eligibility criteria:
inclusion criteria: * resident of hattie larlham center for children with disabilities (hlccd) * previously enrolled in the growth in a facility-based population of children with cerebral palsy study in 2003 exclusion criteria: * resident of hlccd who was not enrolled in the growth in a facility-based population of children with cerebral palsy study

Keywords: cerebral palsy dexa scan bone density
efficacy and safety study in postmenopausal women to determine the lowest effective dose for relief of moderate to severe hot-flushes

Conditions: Hot Flashes

Summary: to determine the lowest effective dose of estradiol by comparing e2/lng (2.2mg/0.69mg) and e2 (1.0mg) dose with placebo in decreasing the frequency and severity of moderate to severe hot flushes in postmenopausal women

this study has previously been posted by berlex, inc. berlex, inc. has been renamed to bayer healthcare pharmaceuticals, inc. bayer healthcare pharmaceuticals, inc.is the sponsor of the trial.

Eligibility criteria:
inclusion criteria: * menopause * reporting a minimum of 7 moderate to severe hot flushes per day for at least 1 week (7 consecutive days), or a minimum of 50 moderate to severe hot flushes per week for at least 1 week (7 consecutive days) exclusion criteria: * hormonal treatment * contraindication to estrogen/progestogen therapy
telomere and telomerase

Conditions: Acute Myeloid Leukemia

Summary: researchers hope to determine if the dna is shortened in your body and determine if there is an increase in the protein that shortens dna called telomerase.

a telomere is a region of repetitive dna at the end of chromosomes, which protects the end of the chromosome from destruction. telomeres can be viewed as the tips on the ends of shoelaces that keep them from unraveling. telomeres compensate for incomplete semi-conservative dna replication at chromosomal ends. in absence of a reparative process, dna sequences would be lost in every replicative phase until they reached a critical level, at which point cell division would stop. loss of telomeres leads to chromosome end-to-end fusion, chromosome re-arrangements, and genome instability. telomerase is a "ribonucleoprotein complex" composed of a protein component and an rna primer sequence which acts to protect the terminal ends of chromosomes. telomerase is the natural enzyme which promotes telomere repair. it is however not active in most cells. it certainly is active though in stem cells, germ cells, hair follicles and in 90 percent of cancer cells. telomerase functions by adding bases to the ends of the telomeres. as a result of this telomerase activity, these cells seem to possess a kind of immortality. progressive shortening or attrition of telomere length with consequent genomic instability leading to cancer has been described in various hematological malignancies including acute and chronic myeloid leukemia. reduced telomere length has been documented in patients with the progressive bm failure syndrome called dyskeratosis congenita. abnormalities in these patients include skin pigmentation, nail dystrophy and leukoplakia. mutations in the telomere maintenance mechanism have been implicated in the pathogenesis of this heterogeneous condition. myelodysplastic syndrome is an acquired clonal stem cell disorder characterized by in-effective hematopoiesis, increased intra-medullary apoptosis and peripheral cytopenia. a number of such patients will eventually develop worsening cytopenia evolving into acute myeloid leukemia. a number of studies have investigated telomerase activity and telomere length in patients with mds and aml. telomere shortening was significantly more pronounced in patients with cytogenetic alterations as compared to patients with normal karyotypes. genomic instability develops with progressive telomere shortening. the telomere attrition related genome instability is a stress that leads to up-regulation of specified dna damage foci. these telomere-associated dna damage points are often called as telomere dysfunction-induced focus (tif).

Eligibility criteria:
inclusion criteria: * diagnosis of advanced myelodysplastic syndrome (mds) or acute myeloid leukemia * must be 18 years of age * must be able to give written informed consent

Keywords: aml mds
pressure injury prevention in ae and pfc

Conditions: Pressure Injury; Military Activity

Summary: this study evaluates the effect of a multilayer skin dressing (mepilex) placed on the sacrum or a fluid filled pad (liquicell) on risk factors for pressure injuries under conditions consistent with military long-distance transport or prolonged field care. participants will be assigned to one of six groups - air transport, air transport on a spinal immobilization surface with or without mepilex or on a field stretcher with or without liquicell.

combat casualties undergoing long distance aeromedical evacuation (ae), particularly casualties who are immobilized because of possible spine injuries, and casualties who required prolonged field care are at increased risk for pressure injuries. the risk factors pressure and shear are potentially modifiable via solutions appropriate for these austere conditions. two interventions (mepilex and liquicell) will be evaluated under conditions simulating military medical transport on a standard stretcher or with spinal immobilization in a vacuum spine board (vsb) or on a military stretcher used under field conditions. mepilex is a multi-layer dressing that can be placed on the skin (sacrum/buttocks) and liquicell is a pad filled with pockets of fluid that is placed under the back and buttocks. the effect of these interventions compared to not using them will be studied under the three conditions with or without the intervention (mepilex or liquicell) using measures obtained on the lower back/sacrum including skin interface pressure, oxygen, moisture, and temperature and a cytokine indicating possible tissue damage.

Eligibility criteria:
inclusion criteria: * men and women * age 18 to 55 * meet the physical standards for military personnel * weigh less than 250 pounds * be able to remain in the study position for the duration of the study. exclusion criteria * previous injuries to sacrum/buttocks with scarring * history of pressure injuries * cardiovascular disease * neurological disease that would affect vascular response * diabetes * history of malignancy * current skin condition (e.g., eczema or psoriasis) * current neck/back pain or history of chronic neck/back pain * known vertebral/spinal cord disease/injury (scoliosis, kyphosis, or lordosis) * self-reported pregnancy * concern about ability to remain in the vacuum spine board for 120 minutes

Keywords: pressure injury/prevention military nursing risk reduction
coated vicryl* plus suture compared to chinese silk in scheduled breast cancer surgery

Conditions: Breast Cancer

Summary: this is a 90-day study to evaluate cosmetic outcome and surgical site infection in approximately 100 patients from 6 centers in china undergoing scheduled modified radical mastectomy for breast cancer.

patients will be evaluated post-procedure on days 3, 5, 7, 12, 30 and 90 for cosmetic outcome and surgical site infection.

Eligibility criteria:
inclusion criteria: * 18 years of age or older with written informed consent * scheduled for a modified radical mastectomy * surgical wound classified class i/clean using the cdc ssi surgical wound classification exclusion criteria: * unable to give consent and unlikely to comply with study requirements and complete the 90-day follow up visit * undergoing surgery for modified radical mastectomy with immediate breast reconstruction, cosmetic breast operations, reduction, expansion, insertion of prothesis, duct ectasia or infective breast disease or implant * surgical wounds classified as class ii, iii or iv using cdc ssi surgical wound classification * has inflammatory cancers or skin ulceration * has known allergy or intolerance to triclosan * has compromised wound healing or chronic immune deficiency, for example diabetes, prolonged steroid use, aids or substance abuse * has serious heart and/or lung disease * has skin scar history or family history * has direct relationship to or involvement in this or other studies under the direction of the investigator or center * received an experimental drug or device within 30 days prior to the planned start of treatment

Keywords: wound healing
effects of transcranial temporal interference stimulation on risky decision-making and impulse control in gambling disorder

Conditions: Gambling Disorder

Summary: the purpose of this research is to investigate the effect of transcranial temporal interference stimulation (ttis) targeting the dorsal anterior cingulate cortex in patients with gambling disorder.

this study will apply the emerging non-invasive deep brain stimulation of ttis to the dorsal anterior cingulate cortex in a randomized, double-blind design to demonstrate the possibility of non-invasively targeting the anterior cingulate cortex to modulate impulse control and risky decision-making without activating other regions below the electrodes. additionally, this study will combine the fmri recordings to describe local and network effects on brain activity. specifically, each participant will be assessed at baseline with a scale and t1wi sequence and diffusion tensor imaging, and will randomly receive a combination of stimulation sequentially during the intervention phase, with more than a one-week interval ensuring that there is no interference between each of the two stimulation sequences.

Eligibility criteria:
inclusion criteria: * aged 18-60, male or female, right handed; * with 9 or more years of education, and able to cooperate in completing the questionnaire assessment and behavioural tests. * meets the dsm-5 diagnostic criteria for gambling addiction; * previous gambling behaviour of not less than 1 year's duration (at least one gambling session per week or more); * normal or corrected normal vision and hearing; * agrees to cooperate in completing the follow-up assessment; * no history of neurological problems or head injury; and no skin sensitivity. * agree to cooperate in completing the follow-up assessment; * no metal implantation in the head, no history of neurological problems or head injury, and no skin sensitivity. exclusion criteria: * suffering from severe cognitive dysfunction, such as a history of head trauma, cerebrovascular disease, epilepsy, etc., use of cognitive-promoting medications in the last 6 months; * other psychoactive substance abuse or dependence in the last 5 years (except nicotine).
maternal and fetal outcomes following influenza vaccination in pregnancy

Conditions: Pregnancy Related; Influenza Virus Vaccine Adverse Reaction

Summary: this is a nationwide cohort study to assess maternal and fetal outcomes following vaccination with a quadrivalent influenza vaccine (qiv) during pregnancy.

the korean national immunization program (nip) first introduced quadrivalent influenza immunization for all pregnant women in the 2020-2021 season. this nationwide cohort study is proposed to assess the risks of adverse maternal and fetal outcomes following vaccination with a quadrivalent influenza vaccine (qiv) during pregnancy. we will use the national health insurance database from the national health insurance service (nhis) linked with the national immunization program registry data from the korea centers for diseases control \& prevention (kcdc).

Eligibility criteria:
inclusion criteria: * pregnant women between september 22, 2020, and april 30, 2021. exclusion criteria: * women aged \ 45 years * pregnancies with a chromosomal abnormality * pregnancies with exposure to a known teratogenic medication
evaluation of healthcare workers knowledge regarding their vaccination status at melun hospital

Conditions: Vaccinia

Summary: the goal of this observational study is to learn about the rate the of knowledge of own vaccination status among healthcare workers working at groupe hospitalier sud ile de france. the main question it aims to answer are : knowledge of own vaccination status is less than 50% among healthcare workers working at groupe hospitalier sud ile de france and the assessment of the relationship between healthcare workers of groupe hospitalier sud ile de france and vaccination in general.

healthcare professionals in france are subject to a number of vaccination obligations, and following successive anti-sars-cov2 vaccination campaigns, these obligations are under discussion. even healthcare professionals are reluctant to be vaccinated , particularly in view of annual vaccination rates against seasonal influenza: 22% were vaccinated against seasonal influenza in 2022, and 25.9% knew their general vaccination status. as part of the national "european vaccination week" event organized by the french ministry of health and prevention, we propose a questionnaire designed for hospital healthcare workers to assess their knowledge of their own vaccination status, and evaluate their attitude with vaccination. the link to the questionnaire will be forwarded to staff e-mail addresses, and it will be administered on a one-off basis. at least 100 professionals will be surveyed. each participant is expected to complete the questionnaire in 10 minutes, and the total duration of the research is one week.

Eligibility criteria:
inclusion criteria: * anyone working at ghsif exclusion criteria: * any person refusing to participate
miami membrane for potency (mmep) trial

Conditions: Prostate Cancer

Summary: the use of dehydrated human amnionic membrane allograft improves erectile function recovery (as measured by (sexual history inventory for men (shim) score) at 12 months after robotic assisted radical prostatectomy (rarp) compared to a control group with no allograft.

this is a phase 2 prospective randomized trial investigating the impact of amniotic membrane placement over the neurovascular bundles after bilateral nerve sparing robot assisted radical prostatectomy on potency. the study will have a control arm that will follow standard of care surgery, without placement of any membranes. 70 men will be allocated to each arm. the research study will involve follow up every 3 months for the first 12 months. after this the investigators will follow patients annually with prostate-specific antigen (psa) measurements and an assessment of any secondary therapies for 5 years post-surgery. randomization of study patients will be done in equal proportion to arm i (membrane placement) and arm ii (no membrane placement, standard of care surgery) using a permuted block design stratified by baseline shim score (\ =17), and use of any erectile aids (yes vs. no) in the last 3 months.

Eligibility criteria:
inclusion criteria: * men age 40-80 with localized prostate cancer who are undergoing bilateral nerve sparing rarp at the university of miami exclusion criteria: * men with poor urinary control at baseline requiring the use of pads for leakage * previous treatment for prostate cancer * previous history of pelvic radiation * men who are using non-oral erectile aids such as vacuum pump, intra-cavernous injections, muse, penile prosthesis.

Keywords: prostate cancer amniotic membrane placement robotic assisted radical prostatectomy rarp human amniotic membrane allograft
effect of magnesium alginate in infants with gastroesophageal reflux.

Conditions: Gastro Esophageal Reflux

Summary: recurrent regurgitation stress the infants and their parents and often results in an inappropirate use of ppi prescription in infancy. the aim of this study is to evaluate the efficacy of mg alginate in infants with symptoms of gastroesophageal reflux.


Eligibility criteria:
inclusion criteria: * symptoms suggestive of ger, evaluated through a validated questionnaire (infant gastroesophageal reflux questionnaire revised: i-gerq-r \> 16) * informed consent signed exclusion criteria: * congenital or chronic diseases * use of anti acid drugs
reversibility of minimal hepatic encephalopathy following liver transplantation

Conditions: Minimal Hepatic Encephalopathy

Summary: this study included 20 patients listed for liver transplantation in addition to 20 age- and sex- matched controls. neurological, psychiatric, laboratory and radiological examinations were performed for both patients and controls before and 6 months after liver transplantation. assessment of cognitive functions by trail making test a (tmt a), tmt b, digit symbol test (dst), and serial dotting test (sdt) was done before and after liver transplantation.


Eligibility criteria:
inclusion criteria: * right handed patients with biopsy-proven liver cirrhosis listed for liver transplantation exclusion criteria: * overt hepatic encephalopathy. * significant cortical atrophy or other structural brain changes revealed by conventional neuro-imaging. * regular use of psychotropic drugs, such as benzodiazepines. * known major psychiatric disorder. * less than 6 months of complete alcohol abstinence. * post-transplant toxic levels of immunosuppressive drugs. * patients unable to perform the tests (illiterate or upper limb motor handicaps).
nutritional intervention in malnourished patients with chronic heart failure

Conditions: Heart Failure; Malnutrition

Summary: malnutrition is common in patients with heart failure (hf) and is associated with a worse prognosis. however, there is little information on the impact of nutritional intervention in malnourished patients with heart failure. therefore, the aim of our study is to evaluate whether a specific nutritional intervention has an impact on mortality and hospitalizations, quality of life, nutritional status, and functional capacity in patient with heart failure and malnutrition.

a high prevalence of malnutrition has been reported in hospitalized patients with acute heart failure and some studies suggest that personalized treatments or interventions on nutritional status could improve prognosis in these patients. previous studies have shown that malnutrition is an independent factor associated with worse prognosis not only in hospitalized patients with decompensated hf but also in patients with chronic stable hf. in this sense, it has been postulated that nutritional intervention in malnourished patients with hf could have some prognostic benefit. however, there are very few data published in the literature that have assessed the nutritional status and the benefit of a nutritional intervention in stable ambulatory patients with chronic hf. therefore, the aim of this study was to evaluate whether the application of an educational and nutritional intervention in malnourished patients with heart failure improves prognosis, nutritional status, functional capacity and quality of life.

Eligibility criteria:
inclusion criteria: * patients older than 18 years with a confirmed diagnosis of hf according to current criteria established by clinical practice guidelines and who present left ventricular dysfunction documented by echocardiography (lvef less than 40%). * patients with clinical stability in the last 6 months defined as no admissions or decompensations in the last 6 months. * patients with malnutrition or at risk of malnutrition according to criteria established by the mini nutritional assessment score (see attached). * patients who agree to participate in the study by signing the written informed consent after receiving verbal and written information about the study. exclusion criteria: * \*dementia or severe cognitive impairment. * dialysis. * already receiving nutritional supplements. * known concomitant oncologic process or other concomitant disease with life expectancy of less than 1 year. * pregnant women. * participation in another clinical trial concurrently.

Keywords: malnutrition heart failure nutritional intervention